(7.12.2006) Leif Helth Jensen, the former CEO of Glycom and Co-founder of Neurosearch, Zealand Pharma and Santaris Pharma, is taking the lead as BoD Chairman in one of SEED Capital’s promising portfolio companies: Valderm.

Valderm develops the patented and well-documented compound Valrubicin. Valrubicin is used as a medical therapy for psoriasis and other skin diseases, such as actinic keratosis, characterized by hyperproliferation.

With Leif Helth Jensen as BoD, Valderm will benefit from his strong trade knowledge and experience in a usually very heavily regulated industry.

To read more about Valderm, visit our portfolio description of the company.

For further information, please contact:

Ole Bitsch-Jensen
Investment Manager

Phone: +45 39179410

E-mail: 
obj@seedcapital.dk

(Published: 7 December 2006)